Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors. - sprookjes - yvandenbroek - TriplyDB

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

http://www.wikidata.org/entity/Q33547682

about

Incidence and risk factors of serious adverse events during antituberculous treatment in Rwanda: a prospective cohort study Outcomes of comprehensive care for children empirically treated for multidrug-resistant tuberculosis in a setting of high HIV prevalence Complications of antiretroviral therapy initiation in hospitalised patients with HIV-associated tuberculosis Barriers to initiation of antiretrovirals during antituberculosis therapy in Africa.Presentation and outcome of tuberculous meningitis in a high HIV prevalence setting.Assessment at antiretroviral clinics during TB treatment reduces loss to follow-up among HIV-infected patients.Independent predictors of tuberculosis mortality in a high HIV prevalence setting: a retrospective cohort study.Burden of antituberculosis and antiretroviral drug-induced liver injury at a secondary hospital in South Africa Pharmacokinetics of Pyrazinamide and Optimal Dosing Regimens for Drug-Sensitive and -Resistant Tuberculosis.Predictors of mortality in adults on treatment for human immunodeficiency virus-associated tuberculosis in Botswana: A retrospective cohort study.Toxicity associated with tuberculosis chemotherapy in the REMoxTB study

P2860

Q28478173-740BCE43-E572-4A6B-9EB6-4E0FE63A964A Q28483868-16CA1A3F-B862-402C-A1CF-2360226C5FA4 Q28486096-EB0E2FD3-9605-45D4-A662-0C21588310D8 Q33903941-6E7155A5-B865-4F7C-9167-26FE2B2914DA Q33916426-E9584AAE-BA45-4F10-B1CF-E33B5839E5DA Q34311748-5AF04E3C-96F1-4A04-AAE9-D0D4468DE5D5 Q36131547-7F8A97AF-9335-4AB1-A8B5-5F3BD208C214 Q36709012-F8166F64-593D-4B2F-B697-D7C8C613F2F0 Q38729024-AB2EF844-EE9A-4850-830D-28207308A8CD Q53691928-C7D82C09-F25B-4323-865B-9ACB2FE9E904 Q56969466-1A79719B-0B82-4872-B313-7A29ED60D3F1

P2860

Clinical deterioration during antituberculosis treatment in Africa: incidence, causes and risk factors.

http://www.wikidata.org/entity/Q33547682

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Clinical deterioration during ...... ence, causes and risk factors.

@ast

Clinical deterioration during ...... ence, causes and risk factors.

@en

Clinical deterioration during ...... ence, causes and risk factors.

@nl

type

label

Clinical deterioration during ...... ence, causes and risk factors.

@ast

Clinical deterioration during ...... ence, causes and risk factors.

@en

Clinical deterioration during ...... ence, causes and risk factors.

@nl

prefLabel

Clinical deterioration during ...... ence, causes and risk factors.

@ast

Clinical deterioration during ...... ence, causes and risk factors.

@en

Clinical deterioration during ...... ence, causes and risk factors.

@nl

P1433

Q33547682-5FC82A1C-7FA8-443A-B692-8C2F559C01A8

P1476

Q33547682-DB3D82A3-5540-4BEA-82E6-F1332C47252C

P2093

Q33547682-228FDCE4-1728-434D-AB22-CE57AF93D885

Q33547682-3A196E64-789D-423C-8429-09DB798EE458

Q33547682-8B4944A8-6CB9-4FCB-8214-F1E5E3B946B1

Q33547682-9BE8B08E-5ED3-47B7-A42C-68A14CF33219

Q33547682-AA7EB569-451C-4FFE-B0A4-0E5AE88AE8CC

Q33547682-D308AF95-FDF1-4C11-91CD-39AC3CD2DA15

Q33547682-D8A9362E-9C29-4BD2-B75A-2A4E0661ABE7

P2860

Q33547682-079D37EF-30C6-4128-8BA1-42470D14E7E8

Q33547682-185BFE5E-7037-406B-9032-3EAC49D58BF0

Q33547682-1AB60C1B-B664-4A19-8A9C-221FF436B2E8

Q33547682-1DAB5D3D-6DF2-47BA-B002-A9ECC1E113F1

Q33547682-30E599AA-AA89-42C1-B352-02160071931F

Q33547682-36CA33EE-D793-4134-A7D9-15EB2ED7BEB2

Q33547682-5329310E-58AD-4CCF-A41D-A0A137103281

Q33547682-56AC913C-09C4-4A79-A0E3-AD7A30CFD52D

Q33547682-60E121D7-F060-4F98-B560-A315428BE5C5

Q33547682-6C15523F-A606-437E-9A3A-4FD487E33EDA

P2888

Q33547682-EBD05814-34E8-49D2-8546-C555F1939F9F

P304

Q33547682-8D924D4B-B012-4B68-83A0-52BCACC01D9C

P31

Q33547682-FEF83C65-80B6-4D14-8983-C874832666CD

P356

Q33547682-9BB8313C-ADC2-4FFC-9FB5-F79188CEB17D

P478

Q33547682-B30DD921-6055-423D-973A-42E11A99C0DA

P50

Q33547682-3B96FA0C-7BFD-4057-905E-F4D16131DBBF

Q33547682-46288A2E-2D36-46C0-AC07-F63FE060F2CA

Q33547682-6C56C0FD-4EC5-4352-B8E3-DEF2AC4C99CB

Q33547682-9B4E0F77-2A76-44B8-8D5D-DC337F0D4873

Q33547682-AD535752-205A-4CF4-B168-8D6D01134051

P577

Q33547682-B40D2780-1E2F-4CED-B4EA-398484FF4B6B

P5875

Q33547682-70489C0E-06FE-4E1F-AF45-5B6A5F6007AF

P6179

Q33547682-76B5A0ED-2773-4737-BA18-0BA678710B2C

P698

Q33547682-C0B2A3EA-6E5C-4C67-8164-0E49F394557F

P932

Q33547682-AA286486-8974-437A-A896-8F95817C86DC

P356

1471-2334-10-83

P1433

BMC Infectious Diseases

P1476

Clinical deterioration during ...... ence, causes and risk factors.

@en

P2093

Cheryl McDermid

http://www.w3.org/2001/XMLSchema#string

Dominique J Pepper

http://www.w3.org/2001/XMLSchema#string

Feriyl Bhaijee

http://www.w3.org/2001/XMLSchema#string

Janisha Patel

http://www.w3.org/2001/XMLSchema#string

Simiso Sokhela

http://www.w3.org/2001/XMLSchema#string

Suzaan Marais

http://www.w3.org/2001/XMLSchema#string

Virginia De Azevedo

http://www.w3.org/2001/XMLSchema#string

P2860

Clinical deterioration during antitubercular treatment at a district hospital in South Africa: the importance of drug resistance and AIDS defining illnesses

Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings

CD4+ count-guided interruption of antiretroviral treatment

HIV infection and tuberculosis in South Africa: an urgent need to escalate the public health response.

Determinants of rifampin, isoniazid, pyrazinamide, and ethambutol pharmacokinetics in a cohort of tuberculosis patients.

HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis.

Combined therapy for tuberculosis and HIV-1: the challenge for drug discovery.

Antituberculosis drug-induced hepatotoxicity: concise up-to-date review.

Novel relationship between tuberculosis immune reconstitution inflammatory syndrome and antitubercular drug resistance

WHO HIV clinical staging or CD4 cell counts for antiretroviral therapy eligibility assessment? An evaluation in rural Rakai district, Uganda.

P2888

1471-2334-10-83

P304

83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1471-2334-10-83

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Robert J. Wilkinson

Helen McIlleron

Graeme Meintjes

P577

2010-03-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42767751

http://www.w3.org/2001/XMLSchema#string

P6179

1016899922

http://www.w3.org/2001/XMLSchema#string

P698

20353569

http://www.w3.org/2001/XMLSchema#string

P932

2858733

http://www.w3.org/2001/XMLSchema#string